Tivic Health Systems (TIVC) shares soared 220% in Tuesday's premarket after it said discussions with the White House drew "significant positive interest" for potential defense applications for its biologic and bioelectronic product candidates.
The therapeutics company also said it met with the Food and Drug Administration to discuss ways to expedite approval of Entolimod and Entolasta. Entolimod, the firm's lead drug candidate is intended to treat neutropenia.